Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:69321rdf:typepubmed:Citationlld:pubmed
pubmed-article:69321lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:69321lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:69321lifeskim:mentionsumls-concept:C0376249lld:lifeskim
pubmed-article:69321pubmed:issue6lld:pubmed
pubmed-article:69321pubmed:dateCreated1977-8-12lld:pubmed
pubmed-article:69321pubmed:abstractTextHistocompatibility antigen (HLA) phenotypes of 34 patients with Ph1+ chronic myelogenous leukemia (CML) were evaluated for association with HLA antigens. Two control populations were compared to the CML patients: 142 normal volunteer platelet donors, and 160 normal donors of granulocyte transfusions. HLA typing was done by lymphocyte microcytotoxicity tests for nine antigens on sublocus A and 15 antigens on sublocus B. HLA-B7 and HLA-B12 were decreased in CML patients compared to both platelet and granulocyte donors. There was increased frequency of HLA-A3 in patients (41%) as compared to controls (25% and 33%); HLA-B5 - patients = 20%; controls 8% and 6%; and HLA-BW17 - patients = 17%; controls = 6% and 3% (P = 0.01). Median survival was 24+ months and independent of HLA. HLA-B5 and HLA-BW17 were significantly increased in patients with CML compared to two normal control populations. No increase in HLA-B8 was seen. Decreased frequency of HLA-B7 and B12 was noted. The significance of these differences is being evaluated.lld:pubmed
pubmed-article:69321pubmed:languageenglld:pubmed
pubmed-article:69321pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:69321pubmed:citationSubsetAIMlld:pubmed
pubmed-article:69321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:69321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:69321pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:69321pubmed:statusMEDLINElld:pubmed
pubmed-article:69321pubmed:monthJunlld:pubmed
pubmed-article:69321pubmed:issn0038-4348lld:pubmed
pubmed-article:69321pubmed:authorpubmed-author:McCredieK BKBlld:pubmed
pubmed-article:69321pubmed:authorpubmed-author:FreireichE...lld:pubmed
pubmed-article:69321pubmed:authorpubmed-author:TrujilloJJlld:pubmed
pubmed-article:69321pubmed:authorpubmed-author:HesterJ PJPlld:pubmed
pubmed-article:69321pubmed:authorpubmed-author:RossenRRlld:pubmed
pubmed-article:69321pubmed:issnTypePrintlld:pubmed
pubmed-article:69321pubmed:volume70lld:pubmed
pubmed-article:69321pubmed:ownerNLMlld:pubmed
pubmed-article:69321pubmed:authorsCompleteYlld:pubmed
pubmed-article:69321pubmed:pagination691-3lld:pubmed
pubmed-article:69321pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Hu...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ch...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Le...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Fe...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ma...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Te...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ch...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ep...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ge...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Ch...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-Hi...lld:pubmed
pubmed-article:69321pubmed:meshHeadingpubmed-meshheading:69321-HL...lld:pubmed
pubmed-article:69321pubmed:year1977lld:pubmed
pubmed-article:69321pubmed:articleTitleFrequency of HLA antigens in chronic myelocytic leukemia.lld:pubmed
pubmed-article:69321pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:69321lld:pubmed